1-12 of 12
Christopher J. Lord
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth

Anthony Cheung, Alicia M. Chenoweth, Annelie Johansson, Roman Laddach, Naomi Guppy, Jennifer Trendell, Benjamina Esapa, Antranik Mavousian, Blanca Navarro-Llinas, Syed Haider, Pablo Romero-Clavijo, Ricarda M. Hoffmann, Paolo Andriollo, Khondaker M. Rahman, Paul Jackson, Sophia Tsoka, Sheeba Irshad, Ioannis Roxanis, Anita Grigoriadis, David E. Thurston, Christopher J. Lord, Andrew N. J. Tutt, Sophia N. Karagiannis
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3298–3315.
https://doi.org/10.1158/1078-0432.CCR-23-3110
Published: 01 August 2024
View article titled, Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth
Open the PDF for Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth in another window
Includes: Multimedia, Supplementary data
Journal Articles

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Violeta Serra, Anderson T. Wang, Marta Castroviejo-Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J. Pettitt, Krishna C. Bulusu, Jenni Nikkilä, Zena Wilson, Adina Hughes, Paul W.G. Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodríguez, Judit Grueso, Joaquin Arribas, Javier Cortés, Cristina Saura, Alan Lau, Susan Critchlow, Brian Dougherty, Carlos Caldas, Gordon B. Mills, J. Carl Barrett, Josep V. Forment, Elaine Cadogan, Christopher J. Lord, Cristina Cruz, Judith Balmaña, Mark J. O'Connor
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4536–4550.
https://doi.org/10.1158/1078-0432.CCR-22-0568
Published: 14 October 2022
View article titled, Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Open the PDF for Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract IA14: Exploiting synthetic lethality in the treatment of gynecologic cancers

Christopher J. Lord
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): IA14.
https://doi.org/10.1158/1557-3265.OVCA17-IA14
Published: 01 August 2018
View article titled, Abstract IA14: Exploiting synthetic lethality in the treatment of gynecologic cancers
Journal Articles

Abstract NTOC-093: SYNTHETIC LETHAL APPROACHES TO TARGET ARID1A DEFICIENT OVARIAN CANCERS

Saira Khalique, Chris T. Williamson, Helen Pemberton, Patty T. Wai, Malini Menon, Rachel Brough, Andri Leonidou, Barrie Peck, Susana Banerjee, Rachael C. Natrajan, Christopher J. Lord
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): NTOC-093.
https://doi.org/10.1158/1557-3265.OVCASYMP16-NTOC-093
Published: 31 May 2017
View article titled, Abstract NTOC-093: SYNTHETIC LETHAL APPROACHES TO TARGET ARID1A DEFICIENT OVARIAN CANCERS
Journal Articles

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

Joo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda High, Ronnie Shapira-Frommer, Vincent Castonguay, Jacques De Greve, Tina Atkinson, Timothy A. Yap, Shahneen Sandhu, Susana Banerjee, Lee-May Chen, Michael L. Friedlander, Bella Kaufman, Amit M. Oza, Ursula Matulonis, Louise J. Barber, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, James Campbell, Lina Chen, Johann S. de Bono, Martin E. Gore, Christopher J. Lord, Alan Ashworth, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5485–5493.
https://doi.org/10.1158/1078-0432.CCR-13-1262
Published: 01 October 2013
View article titled, Efficacy of Chemotherapy in <em>BRCA1/2</em> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Open the PDF for Efficacy of Chemotherapy in <em>BRCA1/2</em> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study in another window
Includes: Supplementary data
Journal Articles

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

Yuqiao Shen, Farah L. Rehman, Ying Feng, Julia Boshuizen, Ilirjana Bajrami, Richard Elliott, Bing Wang, Christopher J. Lord, Leonard E. Post, Alan Ashworth
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (18): 5003–5015.
https://doi.org/10.1158/1078-0432.CCR-13-1391
Published: 16 September 2013
View article titled, BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Open the PDF for BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency in another window
Includes: Supplementary data
Journal Articles

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nicholas Orr, Marina Parton, Ian E. Smith, Jorge S. Reis-Filho, Mitch Dowsett, Alan Ashworth, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 6159–6168.
https://doi.org/10.1158/1078-0432.CCR-10-1027
Published: 16 December 2010
View article titled, A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Open the PDF for A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Therapeutic Targeting of the DNA Mismatch Repair Pathway

Sarah A. Martin, Christopher J. Lord, Alan Ashworth
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (21): 5107–5113.
https://doi.org/10.1158/1078-0432.CCR-10-0821
Published: 31 October 2010
View article titled, Therapeutic Targeting of the DNA Mismatch Repair Pathway
Open the PDF for Therapeutic Targeting of the DNA Mismatch Repair Pathway in another window
Journal Articles

Bringing DNA Repair in Tumors into Focus

Christopher J. Lord, Alan Ashworth
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3241–3243.
https://doi.org/10.1158/1078-0432.CCR-09-0434
Published: 18 May 2009
View article titled, Bringing DNA Repair in Tumors into Focus
Open the PDF for Bringing DNA Repair in Tumors into Focus in another window
Includes: Supplementary data
Journal Articles

Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers

Rachael Natrajan, Maryou B. Lambros, Socorro María Rodríguez-Pinilla, Gema Moreno-Bueno, David S.P. Tan, Caterina Marchió, Radost Vatcheva, Sydonia Rayter, Betania Mahler-Araujo, Laura G. Fulford, Daniela Hungermann, Alan Mackay, Anita Grigoriadis, Kerry Fenwick, Narinder Tamber, David Hardisson, Andrew Tutt, Jose Palacios, Christopher J. Lord, Horst Buerger, Alan Ashworth, Jorge S. Reis-Filho
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (8): 2711–2722.
https://doi.org/10.1158/1078-0432.CCR-08-1878
Published: 15 April 2009
View article titled, Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers
Open the PDF for Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers in another window
Includes: Supplementary data
Journal Articles

PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas

David S.P. Tan, Maryou B.K. Lambros, Sydonia Rayter, Rachael Natrajan, Radost Vatcheva, Qiong Gao, Caterina Marchiò, Felipe C. Geyer, Kay Savage, Suzanne Parry, Kerry Fenwick, Narinder Tamber, Alan Mackay, Tim Dexter, Charles Jameson, W. Glenn McCluggage, Alistair Williams, Ashley Graham, Dana Faratian, Mona El-Bahrawy, Adam J. Paige, Hani Gabra, Martin E. Gore, Marketa Zvelebil, Christopher J. Lord, Stanley B. Kaye, Alan Ashworth, Jorge S. Reis-Filho
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2269–2280.
https://doi.org/10.1158/1078-0432.CCR-08-2403
Published: 01 April 2009
View article titled, PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas
Open the PDF for PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas in another window
Includes: Supplementary data
Journal Articles

Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy

Christopher J. Lord, Michelle D. Garrett, Alan Ashworth
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4463–4468.
https://doi.org/10.1158/1078-0432.CCR-06-1269
Published: 09 August 2006
View article titled, Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy
Open the PDF for Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy in another window